Sort   by:  
 Page size 
UnknownA randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Not available
S-EPMC4143093 | biostudies-literature
UnknownPembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Not available
S-EPMC12140401 | biostudies-literature
UnknownAfatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
Not available
S-EPMC6927323 | biostudies-literature
UnknownMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Not available
S-EPMC8386522 | biostudies-literature
Sort   by:  
 Page size